|  |  |  |  |
| --- | --- | --- | --- |
| Порядковый номер ссылки | Авторы, название публикации и источника, где она опубликована, выходные данные | ФИО, название публикации и источника на английском | Полный интернет-адрес (URL) цитируемой статьи или ее doi. |
| 1 | Бельтюкова А.С., Сысоев К.А., Ильина Т.Н., Шемеровская Т.Г., Хобейш М.М., Монахов К.Н., Тотолян А.А. Экспрессия мРНК хемокинов и хемокиновых рецепторов в коже больных псориазом. Медицинская иммунология. 2008;10(4-5):337-346. | Beltiukova A.S., Syssoev K.A., Il’ina T.N., Shemerovskaya T.G., Hobeish M.M., Monakhov K.N., Totolian A.A. EXPRESSION OF mRNAS FOR CHEMOKINES AND CHEMOKINE RECEPTORS IN THE SKIN FROM PATIENTS WITH PSORIASIS. Medical Immunology (Russia). 2008;10(4-5):337-346. (In Russ.) | [https://doi.org/10.15789/1563-0625-2008-4-5-337-346] |
| 2 | Ковальчук Л. В., Ганковская Л. В., Мешкова Р. Я. Клиническая иммунология и аллергология с основами общей иммунологии. – М.:ГЭОТАР-Медиа, 2014.- стр 640 | Kovalchuk L. V., Gankovskaya L. V., Meshkova R. Ya. Clinical immunology and Allergology with the basics of General immunology. Moscow: GEOTAR-Media, 2014.- 640р |  |
| 3 | Меркушова Е. Д., Хасанова Е. М., Свитич О. А., Баткаева Н. В., Гитинова М. М., Ганковская Л. В. Роль TLR9 и компонентов инфламмасомного комплекса в иммунопатогенезе псориаза// Российский иммунологический журнал.- 2019.- Т.13(22), №2. – С.406-408  | Merkushova E. D., Khasanova E. M., Switich О. А.,Batkaeva N. V., Gitinova M. M., Gankovskaya L. V. The role of TLR9 and components of the inflammasoma complex in immunopathogenesis of psoriasis. Russian Journal of Immunology (Russia).2019; 13(22):406-408  | [https://www.elibrary.ru/item.asp?id=41600456] |
| 4 | Молочков В. А., Бадокин В. В., Альбанова В. И., Волнухин В. А. Псориаз и псориатический артрит. // М.: Т-во научных изданий КМК; Авторская академия. 2007. 298с. | Molochkov V. A., Badokin V. V., Albanova V. I., Volnukhin V. A. Psoriasis and psoriatic arthritis. // M.: T-in scientific publications of the CMC; Author's Academy. 2007. 298c. |  |
| 5 | Смирнова С.В., Смольникова М.В. Иммунопатогенез псориаза и псориатического артрита. Медицинская иммунология. – 2014. – Т.16,№2. –С.127-138. | Smirnova S.V., Smolnikova M.V. IMMUNE PATHOGENESIS OF PSORIASIS AND PSORIATIC ARTHRITIS. Medical Immunology (Russia). 2014;16(2):127-138. (In Russ.) | [https://doi.org/10.15789/1563-0625-2014-2-127-138] |
| 6 | Ярилин А. А. Иммунология: учебник. / А.А. Ярилин//М.: ГОЭТАР-Медиа, 2010. – 752 с. | Yarilin A. A. Immunology: textbook. / A. A. Yarilin/ / Moscow: GEOTAR-Media, 2010. - 752 p. |  |
| 7 | Anwar M. A., Basith S., Choi S. Negative regulatory approaches to the attenuation of Toll-like receptor signaling. Exp Mol Med., 2013, Vol.45, no.2, pp 1-14 |  | [https://doi.org/10.1038/emm.2013.28] |
| 8 | Franck J. Barrat , Thea Meeker , Josh Gregorio , Jean H. Chan , Satoshi Uematsu , Shizuo Akira , Bonnie Chang , Omar Duramad , Robert L. Coffman. Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus. J Exp Med, 2005, Vol 202, no. 8, pp. 1131–1139  |  | [https://doi.org/10.1084/jem.20050914] |
| 9 | Bauernfeind F. Of inflammasomes and pathogens--sensing of microbes by the inflammasome. EMBO Mol Med., 2013, Vol 5, no.6, pp. 14-26. |  | [https://doi.org/10.1002/emmm.201201771] |
| 10 | Bianchi M. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol., 2007, Vol.81(1), pp. 1-5. |  | [https://doi.org/10.1189/jlb.0306164] |
| 11 | Boxer MB, Shen M, Auld DS, Wells JA, Thomas CJ. A Small Molecule Inhibitor of Caspase 1. Probe Reports from the NIH Molecular Libraries Program. Bethesda, MD: National Center for Biotechnology Information 2010 |  | [https://www.ncbi.nlm.nih.gov/books/NBK56241/] |
| 12 | Cohen S., Fleischmann R.  Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol., 2010, Vol. 22, no. 2, pp. 330-335 |  | [doi: 10.1097/BOR.0b013e3283378e6f] |
| 13 | Curry JL, Qin JZ, Bonish B, et al. Innate immunerelated receptors in normal and psoriatic skin. Arch Pathol Lab Med, 2003, Vol. 127, pp. 178–186 |  |  |
| 14 | Daniels MJ, Rivers-Auty J, Schilling T, Spencer NG, Watremez W, Fasolino V, et al. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models. Nat Commun., 2016, Vol.7, no. 12504 |  | [https://doi.org/10.1038/ncomms12504] |
| 15 | Darakhshan S, Pour AB. Tranilast: a review of its therapeutic applications. Pharmacol Res., 2015, Vol. 91, pp.15–28.  |  | [https://doi.org/10.1016/j.phrs.2014.10.009] |
| 16 | Di Virgilio F. The Therapeutic Potential of Modifying Inflammasomes and NOD-Like Receptors. Pharmacol Rev. 2013, Vol. 65, no.3, pp. 872-905. |  | <http://pharmrev.aspetjournals.org/content/65/3/872>[https://doi.org/10.1124/pr.112.006171] |
| 17 | Dombrowski Y., Peric M., Koglin S., Kammerbauer C., Göss C., Anz D. Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. / Sci Transl Med., 2011, Vol. 3, no. 82, pp. 82ra38 |  | [<https://doi.org/10.1126/scitranslmed.3002001>]<https://stm.sciencemag.org/content/3/82/82ra38> |
| 18 | Fischer, U., Schulze-Osthoff, K. Apoptosis-based therapies and drug targets. Cell Death Differ ., 2005, Vol. 12, pp. 942–961. |  | [doi: 10.1038/sj.cdd.4401556] |
| 19 | Fritz J.H., Girardin S.E., Fitting C., Werts C., Mengin-Lecreulx D., Caroff M. et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists // Eur J Immunol., 2005, Vol. 35, no.8, pp.2459-2470. |  | [<https://doi.org/10.1002/eji.200526286>]<https://onlinelibrary.wiley.com/doi/full/10.1002/eji.200526286> |
| 20 | Garshick MS, Barrett TJ, Wechter T Inflammasome Signaling and Impaired Vascular Health in Psoriasis. Arterioscler Thromb Vasc Biol., 2019, Vol. 39, no.4, pp. 787-798 |  | [<https://doi.org/10.1161/ATVBAHA.118.312246>]<https://www.ahajournals.org/doi/10.1161/ATVBAHA.118.312246> |
| 21 | Hari A., Flach T.L., Shi Y., Mydlarski P.R. Toll-Like Receptors: Role in Dermatological Disease. Mediators Inflamm., 2011 Vol.2010, ID437246 |  | [<https://doi.org/10.1155/2010/437246>]https://www.hindawi.com/journals/mi/2010/437246/ |
| 22 | He Y, Varadarajan S, Muñoz-Planillo R, Burberry A, Nakamura Y, Núñez G. 3, 4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014, Vol. 289, pp. 1142–1150.  |  | [doi: 10.1074/jbc.M113.515080] |
| 23 | Heinrich M, Robles M, West JE, Ortiz de Montellano BR, Rodriguez E. Ethnopharmacology of Mexican asteraceae (compositae). Ann Rev Pharmacol Toxicol.,1998, Vol. 38, pp. 539–65.  |  | [doi: 10.1146/annurev.pharmtox.38.1.539] |
| 24 | Huang Y, Jiang H, Chen Y, Wang X, Yang Y, Tao J, et al. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol Med., 2018, Vol.10, e8689 |  | [doi: 10.15252/emmm.201708689] |
| 25 | Ioannidis I., Ye F., McNally B., Willette M., Flaño E. Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J Virol., 2013, Vol.87, no.6, pp. 3261–3270. |  | <https://jvi.asm.org/content/87/6/3261>**[DOI:** 10.1128/JVI.01956-12] |
| 26 | Janeway C.A. Jr., Medzhitov R. Innate immune recognition. Annu Rev Immunol., 2002, Vol. 20, pp.197-216 |  | [DOI: 10.1146/annurev.immunol.20.083001.084359] |
| 27 | Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu J-W, et al. Anti-inflammatory compounds parthenolide and Bay 11–7082 are direct inhibitors of the inflammasome. J Biol Chem., 2010, Vol. 285, pp. 9792–802 |  | [doi: 10.1074/jbc.M109.082305] |
| 28 | Kamata M, Tada Y. Safety of biologics in psoriasis J Dermatol., 2018, Vol. 45, no. 3, pp.279-286.  |  |  [doi: 10.1111/1346-8138.14096] |
| 29 | Kuwar R, Rolfe A, Di L, Xu H, He L, Jiang Y, et al. A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury. J Neuroinflamm. 2019, Vol. 16, Article no. 81.  |  | [doi: 10.1186/s12974-019-1471-y] |
| 30 | Lai C.Y., Su Y.W., Lin K.I., Hsu L.C., Chuang T.H. Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation. J Immunol Res., 2017, Vol. 2017, Article ID 7807313. |  | [https://doi.org/10.1155/2017/7807313] |
| 31 | Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol., 2009, Vol.187, pp. 61–70.  |  | [doi: 10.1083/jcb.200903124] |
| 32 | Lee C.C. Accessory molecules for Toll-like receptors and their function. Lee C.C., Avalos A.M., Ploegh H.L. Nat Rev Immunol., 2012, Vol. 12, no.3, pp. 168–179. |  | [<https://doi.org/10.1038/nri3151>]<https://www.nature.com/articles/nri3151> |
| 33 | Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature, 2016, Vol. 535, pp. 153–8.  |  | [doi: 10.1038/nature18629] |
| 34 | Lowes M. A ., Suárez-Fariñas M., Krueger J. G. Immunology of Psoriasis. Annu Rev Immunol., 2014, Vol. 32, pp. 227–255. |  | https://doi.org/10.1146/annurev-immunol-032713-120225 |
| 35 | Mabuchi T., Timothy W. Chang, Suzanne Quinter, Sam T. Hwang Chemokine receptors in the pathogenesis and therapy of psoriasis Journal of Dermatological Science, 2012, Vol. 65, Issue 1, pp. 4-11 |  | [https://doi.org/10.1016/j.jdermsci.2011.11.007] |
| 36 | Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, et al. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci USA, 2018, Vol 115, pp. 1530–9 |  | [doi: 10.1073/pnas.1716095115] |
| 37 | Medzhitov R. TLR-mediated innate immune recognition. Semin Immunol., 2007, Vol. 19, no.1, pp. 1–2. |  | <https://www.sciencedirect.com/science/article/pii/S1044532307000061?via%3Dihub>[doi: 10.1016/j.smim.2007.02.001] |
| 38 | Miller L. S. . Toll-like receptors in skin. Adv Dermatol., 2008,Vol. 24, pp. 71–87. |  | <https://linkinghub.elsevier.com/retrieve/pii/S0882088008000084>[<https://doi.org/10.1016/j.yadr.2008.09.004>] |
| 39 | Mullen L.M., Chamberlain G., Sacre S. Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease. Arthritis Res Ther., 2015, Vol. 17, no.1, pp.122. |  | [<https://doi.org/10.1186/s13075-015-0645-y><https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-015-0645-y>] |
| 40 | Nair R.P., Henseler T., Jenisch S., et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet., 1997, Vol. 6, no.8, pp.1349-56. |  | [<https://doi.org/10.1093/hmg/6.8.1349><https://academic.oup.com/hmg/article/6/8/1349/2901395>] |
| 41 | Oviedo-Boyso J., Bravo-Patiño A., Baizabal-Aguirre V.M. Collaborative Action of Toll-Like and Nod-Like Receptors as Modulators of the Inflammatory Response to Pathogenic Bacteria. Mediators Inflamm., 2014, Vol. 2014, Article ID 432785 |  | [<https://doi.org/10.1155/2014/432785><https://www.hindawi.com/journals/mi/2014/432785/>] |
| 42 | Perregaux DG, McNiff P, Laliberte R, Hawryluk N, Peurano H, Stam E, et al. Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J Pharmacol Exp Ther., 2001, Vol. 299, pp.187–97. |  | <http://jpet.aspetjournals.org/content/299/1/187.long> |
| 43 | Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science, 2005, Vol. 310, pp. 850–5.  |  | [doi: 10.1126/science.1117634] |
| 44 | Reinholz M., Ruzicka T., Schauber J. Cathelicidin LL-37: An Antimicrobial Peptide with a Role in Inflammatory Skin Disease. Ann Dermatol. 2012, Vol. 24, no. 2, pp. 126–135. |  | [<http://dx.doi.org/10.5021/ad.2012.24.2.126>] |
| 45 | Riddle MC. Editorial: sulfonylureas differ in effects on ischemic preconditioning–is it time to retire glyburide? J Clin Endocrinol Metab., 2003, Vol.88, pp. 528–30.  |  | [doi: 10.1210/jc.2002-021971] |
| 46 | Rudolphi K, Gerwin N, Verzijl N, Kraan PVD, Berg WVD. Pralnacasan, an inhibitor of interleukin-1β converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage, 2003, -Vol. 11, pp. 738–46.  |  | [doi: 10.1016/S1063-4584(03)00153-5] |
| 47 | Saïd-Sadier N., Ojcius D.M. Alarmins, inflammasomes and immunity. Biomed J., 2012, Vol. 35, no.6, pp. 437-49. |  | [<https://doi.org/10.4103/2319-4170.104408>]<http://biomedj.cgu.edu.tw/pdfs/2012/35/6/images/BiomedJ_2012_35_6_437_104408.pdf> |
| 48 | Salskov-Iversen ML, Johansen C, Kragballe K, Iversen L. Caspase-5 Expression Is Upregulated in Lesional Psoriatic Skin. J Invest Dermatol., 2011, Vol. 131, pp. 670–676 |  | [<https://doi.org/10.1038/jid.2010.370>]<https://www.sciencedirect.com/science/article/pii/S0022202X15352040> |
| 49 | Siegmund B, Zeitz M. Pralnacasan (vertex pharmaceuticals). IDrugs, 2003, Vol. 6, pp. 154–158 |  | http://europepmc.org/article/med/12789619 |
| 50 | Su F., Xia Y., Huang M., Zhang L., Chen L. Expression of NLPR3 in Psoriasis Is Associated with Enhancement of Interleukin-1β and Caspase-1. Med Sci Monit., 2018, Vol. 24, pp. 7909–7913. |  | <https://www.medscimonit.com/abstract/index/idArt/911347>[DOI: 10.12659/MSM.911347] |
| 51 | Takagi M., Takakubo Y., Pajarinen J., Naganuma Y., Oki H., Maruyama M., Goodman S.B. Danger of frustrated sensors: Role of Toll-like receptors and NOD-like receptors in aseptic and septic inflammations around total hip replacements. J Orthop Translat., 2017, Vol. 10, pp 68–85. |  | [https://doi.org/10.1016/j.jot.2017.05.004]<https://www.sciencedirect.com/science/article/pii/S2214031X1630273X?via%3Dihub> |
| 52 | Takeuchi O., Akira S. Pattern Recognition Receptors and Inflammation. Cell, 2010, Vol. 140, Issue 6, pp. 805-820 |  | [<https://doi.org/10.1016/j.cell.2010.01.022>]<https://www.sciencedirect.com/science/article/pii/S0092867410000231?via%3Dihub> |
| 53 | Telfer N.R., Chalmers R.J., Whale K., Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol., 1992, Vol. 128, no. 1, pp. 39-42. |  | <https://jamanetwork.com/journals/jamadermatology/article-abstract/553751>[doi:10.1001/archderm.1992.01680110049004] |
| 54 | Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol., 2018, Vol. 15, pp. 203–14 |  | [doi: 10.1038/nrcardio.2017.161] |
| 55 | Tonel G., Conrad C. Interplay between keratinocytes and immune cells-recent insights into psoriasis pathogenesis. Int J Biochem Cell Biol., 2009, Vol. 41, no. 5, pp. 963-8. |  | <https://linkinghub.elsevier.com/retrieve/pii/S135727250800438X>[<https://doi.org/10.1016/j.biocel.2008.10.022>] |
| 56 | Visscher P., Wray N., Zhang Q., Sklar P., McCarthy M., Brown M., Yang J.10 years of GWAS discovery: biology, function, and translation. Am. J. Hum. Genet., 2017, Vol. 101, pp. 5–22 |  | [<https://doi.org/10.1016/j.ajhg.2017.06.005>]<https://www.sciencedirect.com/science/article/pii/S0002929717302409?via%3Dihub> |
| 57 | Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, et al. (S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhi. J Pharmacol Exp Ther., 2007, Vol. 321, pp. 509–16 |  | [<https://doi.org/10.1124/jpet.106.111344>]<http://jpet.aspetjournals.org/content/321/2/509> |
| 58 | Williams A., Flavell R.A., Eisenbarth S.C. The role of NOD-like Receptors in shaping adaptive immunity. Curr Opin Immunol., 2010, Vol. 22, no. 1, pp. 34-40 |  | <https://linkinghub.elsevier.com/retrieve/pii/S0952791510000051>[<https://doi.org/10.1016/j.coi.2010.01.004>] |
| 59 | Xiao J, Wang C, Yao JC, et al. Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice. Plos Biology., 2018, Vol.16, no. 11, e3000047. |  | [doi: 10.1371/journal.pbio.3000047]<https://europepmc.org/article/med/30388107> |
| 60 | Yamaoka K. , Tanaka Y.  Jak inhibitor; possibility and mechanism as a new disease modifying anti-rheumatic drug. Jpn. J. Clin. Immunology, 2009, Vol. 32, no. 2, pp. 85-91 |  | <https://doi.org/10.2177/jsci.32.85><https://www.jstage.jst.go.jp/article/jsci/32/2/32_2_85/_article/-char/ja/> |
| 61 | Youm Y-H, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease. Nat Med., 2015, Vol. 21, pp. 263–9.  |  | [doi: 10.1038/nm.3804]<https://www.nature.com/articles/nm.3804> |